Limits...
Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.

Sun S, Liang X, Zhang X, Liu T, Shi Q, Song Y, Jiang Y, Wu H, Jiang Y, Lu X, Pang D - Br. J. Cancer (2015)

Bottom Line: High PGK1 expression was significantly associated with higher histologic grade (P=0.009) and positive status of ER (P=0.004), Her-2 (P=0.026) and P53 (P=0.012).High levels of PGK1 expression were associated with worse overall survival (OS, P=0.02).Multivariate analysis indicated that PGK1 (P=0.001) was an independent predictor in the patients treated with paclitaxel.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.

ABSTRACT

Background: Phosphoglycerate kinase-1 (PGK1) has been recently documented in various malignancies; however, the molecular mechanisms of the variable PGK1 expression and its clinical significance in terms of survival status remain unclear.

Methods: Real-time quantitative PCR (real-time qPCR) and western blotting were used to verify PGK1 expression in 46 fresh breast cancer tissues and matched normal tissues. A tissue microarray (TMA) comprising 401 breast cancer tissues and 123 matched normal tissues was investigated by immunohistochemistry for PGK1 expression. Then, the correlation between PGK1 expression and the clinicopathologic features was analysed.

Results: PGK1 mRNA and protein expression were significantly increased in breast cancer tissues compared with that in normal breast tissues. High PGK1 expression was significantly associated with higher histologic grade (P=0.009) and positive status of ER (P=0.004), Her-2 (P=0.026) and P53 (P=0.012). High levels of PGK1 expression were associated with worse overall survival (OS, P=0.02). Furthermore, patients who underwent paclitaxel chemotherapy with high levels PGK1 expression had shorter OS than did those with low levels of PGK1 expression (P<0.001). Multivariate analysis indicated that PGK1 (P=0.001) was an independent predictor in the patients treated with paclitaxel.

Conclusions: PGK1 is a prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.

Show MeSH

Related in: MedlinePlus

Immunohistochemical staining of PGK1 in breast tissues ( × 400). (A) PGK1 low-expression specimen (normal breast tissue). (B) PGK1 high-expression specimen (breast cancer tissue).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4402453&req=5

fig2: Immunohistochemical staining of PGK1 in breast tissues ( × 400). (A) PGK1 low-expression specimen (normal breast tissue). (B) PGK1 high-expression specimen (breast cancer tissue).

Mentions: The difference in PGK1 expression between the cancer and normal tissues reflected at the protein level was investigated using western blotting and IHC. Overall, breast cancer tissues exhibited dramatically higher levels of PGK1 protein expression compared with normal tissues. Western blotting assays demonstrated that PGK1 exhibited high expression in cancer tissues compared with the normal tissues (Figure 1B). Immunohistochemistry (IHC) analysis showed high expression of PGK1 in 136 of the cancer specimens (33.9%). However, of the 123 normal specimens, we found high PGK1 expression only in 10 (8.1%) samples (P<0.001). Figures 2A and B show representative images of PGK1 staining in cancer tissue from a cancer patient and matched normal breast tissue, respectively.


Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.

Sun S, Liang X, Zhang X, Liu T, Shi Q, Song Y, Jiang Y, Wu H, Jiang Y, Lu X, Pang D - Br. J. Cancer (2015)

Immunohistochemical staining of PGK1 in breast tissues ( × 400). (A) PGK1 low-expression specimen (normal breast tissue). (B) PGK1 high-expression specimen (breast cancer tissue).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4402453&req=5

fig2: Immunohistochemical staining of PGK1 in breast tissues ( × 400). (A) PGK1 low-expression specimen (normal breast tissue). (B) PGK1 high-expression specimen (breast cancer tissue).
Mentions: The difference in PGK1 expression between the cancer and normal tissues reflected at the protein level was investigated using western blotting and IHC. Overall, breast cancer tissues exhibited dramatically higher levels of PGK1 protein expression compared with normal tissues. Western blotting assays demonstrated that PGK1 exhibited high expression in cancer tissues compared with the normal tissues (Figure 1B). Immunohistochemistry (IHC) analysis showed high expression of PGK1 in 136 of the cancer specimens (33.9%). However, of the 123 normal specimens, we found high PGK1 expression only in 10 (8.1%) samples (P<0.001). Figures 2A and B show representative images of PGK1 staining in cancer tissue from a cancer patient and matched normal breast tissue, respectively.

Bottom Line: High PGK1 expression was significantly associated with higher histologic grade (P=0.009) and positive status of ER (P=0.004), Her-2 (P=0.026) and P53 (P=0.012).High levels of PGK1 expression were associated with worse overall survival (OS, P=0.02).Multivariate analysis indicated that PGK1 (P=0.001) was an independent predictor in the patients treated with paclitaxel.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.

ABSTRACT

Background: Phosphoglycerate kinase-1 (PGK1) has been recently documented in various malignancies; however, the molecular mechanisms of the variable PGK1 expression and its clinical significance in terms of survival status remain unclear.

Methods: Real-time quantitative PCR (real-time qPCR) and western blotting were used to verify PGK1 expression in 46 fresh breast cancer tissues and matched normal tissues. A tissue microarray (TMA) comprising 401 breast cancer tissues and 123 matched normal tissues was investigated by immunohistochemistry for PGK1 expression. Then, the correlation between PGK1 expression and the clinicopathologic features was analysed.

Results: PGK1 mRNA and protein expression were significantly increased in breast cancer tissues compared with that in normal breast tissues. High PGK1 expression was significantly associated with higher histologic grade (P=0.009) and positive status of ER (P=0.004), Her-2 (P=0.026) and P53 (P=0.012). High levels of PGK1 expression were associated with worse overall survival (OS, P=0.02). Furthermore, patients who underwent paclitaxel chemotherapy with high levels PGK1 expression had shorter OS than did those with low levels of PGK1 expression (P<0.001). Multivariate analysis indicated that PGK1 (P=0.001) was an independent predictor in the patients treated with paclitaxel.

Conclusions: PGK1 is a prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.

Show MeSH
Related in: MedlinePlus